01—Abstract
Summary
Summary of the 8-K filed April 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck reported first-quarter 2025 results on April 24, 2025, with worldwide sales of $15.5 billiona, down 2% from the prior year but up 1% excluding foreign exchange.
The top-line picture was mixed: KEYTRUDA grew 4% to $7.2 billionb (6% ex-FX) and WINREVAIR launched to $280 million in its first full year of U.S. uptake, while GARDASIL/GARDASIL 9 fell 41% to $1.3 billion, driven mainly by lower demand in China. Animal Health (+5%) and Other Revenues (+17%, helped by out-licensing payments) were bright spots. Profitability held up well, with GAAP EPS of $2.01 (up 7%) and non-GAAP EPS of $2.22 (up 7%, or 12% ex-FX).
Non-GAAP gross margin improved to 82.2% from 81.2%. Management maintained full-year 2025 sales guidance of $64.1 billion to $65.6 billionc, but lowered non-GAAP EPS guidance to $8.82 to $8.97 from $8.88 to $9.03. The cut reflects a one-time charge of about $0.06 per share tied to an upfront payment for the exclusive license of Hengrui Pharma's oral Lp(a) inhibitor, expected to close in the second quarter of 2025.
Excluding that charge, the EPS outlook would have been unchanged. The outlook also absorbs roughly $200 milliond of incremental tariff costs and about 1% of negative FX impact on sales. Guidance continues to include an expected $0.09 per share charge tied to the LaNova MK-2010 technology-transfer milestone.
For investors, the key items to monitor are the trajectory of GARDASIL in China, the pace of WINREVAIR and KEYTRUDA uptake, upcoming regulatory decisions (subcutaneous pembrolizumab PDUFA date of September 23, 2025, and KEYNOTE-689 head and neck PDUFA date of June 23, 2025), and the execution of Merck's pipeline business development and U.S. manufacturing investments. The company's guidance does not assume additional significant business development deals.
02—Key points
Key Highlights
- Q1 2025 sales of $15.5 billion fell 2% reported but grew 1% excluding FX; the Pharmaceutical segment declined 3%.
- KEYTRUDA sales rose 4% to $7.2 billion (6% ex-FX), driven by earlier-stage indications and offset partly by U.S. wholesaler purchase timing.
- GARDASIL/GARDASIL 9 sales fell 41% to $1.3 billion, mainly on lower China demand; excluding China, sales grew 14%.
- Non-GAAP EPS was $2.22 (up 7%) and GAAP EPS was $2.01 (up 7%); non-GAAP gross margin expanded to 82.2% from 81.2%.
- Full-year 2025 non-GAAP EPS guidance was lowered to $8.82–$8.97 (from $8.88–$9.03) due to a one-time ~$0.06 per share Hengrui license charge; sales guidance of $64.1–$65.6 billion was maintained.
- Outlook absorbs approximately $200 million in incremental tariff costs and roughly 1% negative FX impact on full-year sales.
- WINREVAIR generated $280 million in Q1 sales, and its Phase 3 ZENITH trial showed a 76% risk reduction in the composite endpoint versus placebo.
03—Questions
Frequently Asked Questions
Why did Merck lower its 2025 EPS guidance if sales guidance was unchanged?
The non-GAAP EPS range was reduced by about $0.06 per share to reflect a one-time $200 million upfront payment due at closing of the exclusive license agreement with Hengrui Pharma, expected in Q2 2025. Excluding this charge, the EPS outlook would have been unchanged. Sales guidance was maintained at $64.1–$65.6 billion.
How significant is the GARDASIL decline for Merck's outlook?
GARDASIL/GARDASIL 9 sales fell 41% to $1.3 billion in Q1, primarily due to lower demand in China, where sales were $193 million versus $1.25 billion in the prior-year quarter. Excluding China, sales grew 14%. This makes China demand trends a key variable for investors to track.
What regulatory catalysts are upcoming for Merck?
Merck has an FDA PDUFA date of June 23, 2025 for KEYTRUDA plus standard of care in resectable locally advanced head and neck squamous cell carcinoma (KEYNOTE-689), and a PDUFA date of September 23, 2025 for subcutaneous pembrolizumab. The company also plans to begin submitting applications for the oral doravirine/islatravir HIV regimen by mid-2025.
Does the guidance include future acquisitions or licensing deals?
No. Consistent with past practice, Merck's financial outlook does not assume additional significant potential business development transactions. Any deals completed later in 2025 could affect results relative to guidance.
04—Continue